Developer docs
API playgroundTry for free, no card

Search company profiles

PhotoniCare

Full company profile

uuid00027k6

Namestring
PhotoniCare
Legal namestring
PhotoniCare, Inc.
Websiteurl
photoni.care
Company typeenum
Private
Founded yearint
2013
Descriptiontext

PhotoniCare is a privately held medical device company founded in 2013 that has developed the OtoSight Middle Ear Scope, the first and only FDA-cleared handheld otoscope to provide non-invasive imaging of the middle ear using Optical Coherence Tomography (OCT). The device combines a traditional true-color video otoscope view with a proprietary middle ear scan that detects the presence and characterizes the type and density of fluid behind the eardrum, even in the presence of significant earwax, achieving 90.6% diagnostic accuracy versus roughly 50% for standard otoscopy. PhotoniCare targets frontline pediatric, urgent-care, and family practice clinicians, as well as ENT specialists, addressing the population of children affected by ear infections (more than 80% by age three) and the resulting overuse of antibiotics and unnecessary tympanostomy tube surgeries (over one million annually in the US).

The company's revenue model is built on hardware sales of the OtoSight device combined with a procedure-based revenue stream enabled by unique Category III CPT reimbursement codes (0485T and 0486T), with the company providing dedicated coverage, coding, and appeals support to healthcare providers. Go-to-market combines direct enterprise sales to clinics (including a 'Trailblazer' early-adopter program), international distribution partnerships (Japan and an Australian pilot with an aboriginal population), and an OEM manufacturing relationship with Gentex Corporation. The company was spun out of the University of Illinois at Urbana-Champaign, has received over $6 million in NIH SBIR grants (including AI development funding), raised approximately $15-20 million in equity across multiple rounds through a December 2024 Series B first close, and relocated its headquarters from Champaign, Illinois to Grand Rapids, Michigan in late 2024.

Short descriptiontext

PhotoniCare develops the OtoSight Middle Ear Scope, the first FDA-cleared handheld OCT-based otoscope enabling non-invasive middle ear imaging and fluid detection, serving pediatricians, urgent care, and ENT specialists to improve pediatric ear infection diagnosis and reduce unnecessary antibiotic prescribing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
middle ear imaging devices, optical coherence tomography otoscope, pediatric ear infection diagnosis, handheld medical imaging, otitis media diagnostic tools
Industry1 code
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Optical Instruments & Lenses3827
Product category
Medical Diagnostic Imaging Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1OtoSight Middle Ear Scope Device Sales
TypeHardware Sales
Description

Sale of FDA-cleared medical device hardware for middle ear diagnostics. The handheld OCT otoscope is sold to healthcare providers including pediatricians, urgent care, family practices, and ENT specialists.

biospace.com
2Reimbursement / Procedure Billing
TypeProfessional Services
Description

OtoSight Middle Ear Scope can be billed with two Category III CPT Codes 0485T and 0486T. Company provides dedicated reimbursement support for coverage, coding, and appeals assistance.

photoni.care
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Medical device - quote-based pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed. The OtoSight Middle Ear Scope is sold as a medical device with dedicated reimbursement support for healthcare providers.

photoni.care
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1OtoSight Middle Ear Scope
Description

FDA-cleared handheld diagnostic device using Optical Coherence Tomography (OCT) technology for non-invasive imaging of the middle ear to detect and characterize fluid in patients with suspected ear infections.

photoni.care
Core offering1 text field

PhotoniCare develops and sells the OtoSight Middle Ear Scope, an FDA-cleared handheld medical device that uses Optical Coherence Tomography (OCT) to non-invasively image the middle ear. The device detects the presence or absence of fluid, characterizes fluid type, and visualizes fluid density, even in the presence of significant earwax, achieving 90.6% accuracy versus 50% with standard otoscopy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90.6% accuracy in detecting middle ear effusion (fluid) vs 50% accuracy with standard otoscopy
+2 more records
Product overview1 text field

PhotoniCare offers a single flagship product: the OtoSight Middle Ear Scope, an FDA-cleared handheld medical device that represents the first and only otoscope to provide non-invasive imaging of the middle ear using Optical Coherence Tomography (OCT) technology. The device combines traditional video otoscopy (providing true color views of the ear canal and eardrum) with a proprietary middle ear scan feature that visualizes through the eardrum to detect and characterize fluid. The product targets frontline care clinicians including pediatricians, family practitioners, and urgent care providers, with dedicated versions including models with and without WiFi capability. The technology was developed from research at the University of Illinois and has been validated in multiple peer-reviewed clinical studies.

Product and service1 record
1OtoSight Middle Ear Scope
CategoryMedical Diagnostic Imaging Devices
Description

The OtoSight Middle Ear Scope is a handheld medical device combining true-color video otoscopy with OCT-based middle ear scanning. It enables healthcare providers to visualize through the eardrum to detect and characterize middle ear fluid non-invasively. Designed for pediatricians, family practitioners, urgent care clinicians, and ENT specialists.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Japanese Distribution Partner
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership in Japan for international market expansion. Part of global commercialization strategy.

photoni.care
Strategic tierRegionalTypeStrategic or Co-development Partner
Description

North Carolina Biotechnology Center provided office space, resources, contacts, and support for PhotoniCare's establishment in North Carolina in 2021. Landing Pad provides space to life sciences companies establishing presence in the state.

Strategic tierRegionalTypeStrategic or Co-development Partner
Description

Pilot program in Australia with aboriginal population which has one of the world's highest rates of middle-ear infections in children. Strategic pilot to validate technology in high-need population.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Welch Allyn, now part of Baxter International, is the dominant incumbent in frontline otoscopy with deep pediatric and primary-care distribution. PhotoniCare's former CEO advisory board member Steve Meyer was the last CEO of Welch Allyn, underscoring the competitive and partnership overlap in the otoscope category.

TypeDirect peer
Description

TytoCare offers a handheld, connected telehealth diagnostic device that includes a digital otoscope for remote ear examination, directly competing with OtoSight in enabling clinician visualization of the middle ear. Both companies target pediatric primary care and urgent care with FDA-cleared connected hardware.

TypeDirect peer
Description

Eko Health makes connected, AI-enabled handheld diagnostic devices (initially digital stethoscopes) sold into frontline care with FDA clearances and AI decision-support features. PhotoniCare's OtoSight follows a similar playbook of augmenting a familiar exam tool with novel optical/AI technology for primary-care clinicians.

TypeEmerging player
Description

Butterfly Network commercializes a handheld, AI-enabled point-of-care imaging device (whole-body ultrasound) sold to clinicians with FDA clearance and a recurring software/reimbursement model. PhotoniCare's OtoSight shares the handheld-imaging-plus-AI commercial model and frontline-care target customer base.

TypeEmerging player
Description

Remmie Health develops connected otoscope and ENT home-diagnostic devices for parents and clinicians, targeting pediatric ear infection assessment with smartphone-attached visualization. It overlaps with PhotoniCare on ear imaging for the pediatric segment but from a consumer/telehealth angle rather than clinician OCT.

TypeBroad incumbent
Description

Hillrom, acquired by Baxter, distributes the Welch Allyn otoscope and broader vital-signs product lines into hospitals and physician offices globally. As the entrenched diagnostic-device incumbent in the same exam rooms PhotoniCare targets, it is the primary competitor that could add imaging features to existing otoscopes.

TypeBroad incumbent
Description

Heine is a global manufacturer of high-quality diagnostic instruments including otoscopes used by ENTs and pediatricians. As a long-established otoscope specialist with international distribution, it represents the incumbent product PhotoniCare must displace or differentiate against in clinical purchase decisions.

TypeBroad incumbent
Description

Natus Medical, owner of the Otometrics brand, supplies audiology and hearing-diagnostic equipment including tympanometry and otoacoustic emission systems used alongside otoscopy. PhotoniCare's OCT-based middle-ear imaging competes with and could complement Natus's audiology diagnostic workflow in ENT clinics.

TypeEmerging player
Description

Interacoustics, part of the Demant Group, manufactures clinical audiology and middle-ear analyzers (tympanometry, acoustic reflex) used in ENT and pediatric audiology workflows. It overlaps with PhotoniCare on objective middle-ear diagnostics and the same ENT/pediatric specialist buyer.

10Cue Health
TypeEmerging player
Description

Cue Health developed a connected, FDA-cleared diagnostic hardware platform for point-of-care testing with an emphasis on clinician workflows. Like PhotoniCare, Cue pairs a regulated medical device with a digital/data platform, representing a comparable go-to-market and capital-efficiency archetype.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PhotoniCare

Medical Diagnostic Imaging Devicesphotoni.care

PhotoniCare develops the OtoSight Middle Ear Scope, the first FDA-cleared handheld OCT-based otoscope enabling non-invasive middle ear imaging and fluid detection, serving pediatricians, urgent care, and ENT specialists to improve pediatric ear infection diagnosis and reduce unnecessary antibiotic prescribing.

What PhotoniCare does

PhotoniCare is a privately held medical device company founded in 2013 that has developed the OtoSight Middle Ear Scope, the first and only FDA-cleared handheld otoscope to provide non-invasive imaging of the middle ear using Optical Coherence Tomography (OCT). The device combines a traditional true-color video otoscope view with a proprietary middle ear scan that detects the presence and characterizes the type and density of fluid behind the eardrum, even in the presence of significant earwax, achieving 90.6% diagnostic accuracy versus roughly 50% for standard otoscopy. PhotoniCare targets frontline pediatric, urgent-care, and family practice clinicians, as well as ENT specialists, addressing the population of children affected by ear infections (more than 80% by age three) and the resulting overuse of antibiotics and unnecessary tympanostomy tube surgeries (over one million annually in the US).

The company's revenue model is built on hardware sales of the OtoSight device combined with a procedure-based revenue stream enabled by unique Category III CPT reimbursement codes (0485T and 0486T), with the company providing dedicated coverage, coding, and appeals support to healthcare providers. Go-to-market combines direct enterprise sales to clinics (including a 'Trailblazer' early-adopter program), international distribution partnerships (Japan and an Australian pilot with an aboriginal population), and an OEM manufacturing relationship with Gentex Corporation. The company was spun out of the University of Illinois at Urbana-Champaign, has received over $6 million in NIH SBIR grants (including AI development funding), raised approximately $15-20 million in equity across multiple rounds through a December 2024 Series B first close, and relocated its headquarters from Champaign, Illinois to Grand Rapids, Michigan in late 2024.

PhotoniCare firmographics

Firmographics
Name
PhotoniCare
Legal name
PhotoniCare, Inc.
Website
https://photoni.care
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
PhotoniCare develops the OtoSight Middle Ear Scope, the first FDA-cleared handheld OCT-based otoscope enabling non-invasive middle ear imaging and fluid detection, serving pediatricians, urgent care, and ENT specialists to improve pediatric ear infection diagnosis and reduce unnecessary antibiotic prescribing.
Ownership category
akta.pro rank

PhotoniCare industry classification

Industry
Product category
Medical Diagnostic Imaging Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)

Keywords

  • Middle ear imaging devices
  • Optical coherence tomography otoscope
  • Pediatric ear infection diagnosis
  • Handheld medical imaging
  • Otitis media diagnostic tools

Where PhotoniCare is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices3 records

Markets served

PhotoniCare business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. OtoSight Middle Ear Scope Device Sales: Sale of FDA-cleared medical device hardware for middle ear diagnostics. The handheld OCT otoscope is sold to healthcare providers including pediatricians, urgent care, family practices, and ENT specialists.
  2. Reimbursement / Procedure Billing: OtoSight Middle Ear Scope can be billed with two Category III CPT Codes 0485T and 0486T. Company provides dedicated reimbursement support for coverage, coding, and appeals assistance.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goMedical device - quote-based pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

PhotoniCare product offering

Product offering

Core offering

PhotoniCare develops and sells the OtoSight Middle Ear Scope, an FDA-cleared handheld medical device that uses Optical Coherence Tomography (OCT) to non-invasively image the middle ear. The device detects the presence or absence of fluid, characterizes fluid type, and visualizes fluid density, even in the presence of significant earwax, achieving 90.6% accuracy versus 50% with standard otoscopy.

Product overview

PhotoniCare offers a single flagship product: the OtoSight Middle Ear Scope, an FDA-cleared handheld medical device that represents the first and only otoscope to provide non-invasive imaging of the middle ear using Optical Coherence Tomography (OCT) technology. The device combines traditional video otoscopy (providing true color views of the ear canal and eardrum) with a proprietary middle ear scan feature that visualizes through the eardrum to detect and characterize fluid. The product targets frontline care clinicians including pediatricians, family practitioners, and urgent care providers, with dedicated versions including models with and without WiFi capability. The technology was developed from research at the University of Illinois and has been validated in multiple peer-reviewed clinical studies.

Differentiator

Problem solved

Functional benefit

Brands

  • OtoSight Middle Ear Scope: FDA-cleared handheld diagnostic device using Optical Coherence Tomography (OCT) technology for non-invasive imaging of the middle ear to detect and characterize fluid in patients with suspected ear infections.

Products and services

  • OtoSight Middle Ear Scope The OtoSight Middle Ear Scope is a handheld medical device combining true-color video otoscopy with OCT-based middle ear scanning. It enables healthcare providers to visualize through the eardrum to detect and characterize middle ear fluid non-invasively. Designed for pediatricians, family practitioners, urgent care clinicians, and ENT specialists.

Quantifiable outcome

  • 90.6% accuracy in detecting middle ear effusion (fluid) vs 50% accuracy with standard otoscopy
  • +2 more outcomes

Companies that use PhotoniCare

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

PhotoniCare technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

PhotoniCare partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered regional.

  • Japanese Distribution PartnerregionalChannel Partner/ Reseller/ DistributorDistribution partnership in Japan for international market expansion. Part of global commercialization strategy.
  • NCBiotech Landing PadregionalStrategic or Co-development PartnerNorth Carolina Biotechnology Center provided office space, resources, contacts, and support for PhotoniCare's establishment in North Carolina in 2021. Landing Pad provides space to life sciences companies establishing presence in the state.
  • Australian Aboriginal Health PartnerregionalStrategic or Co-development PartnerPilot program in Australia with aboriginal population which has one of the world's highest rates of middle-ear infections in children. Strategic pilot to validate technology in high-need population.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

PhotoniCare competitors and assessment

Company assessment

Broad incumbents

  • Welch Allyn (Baxter International): Welch Allyn, now part of Baxter International, is the dominant incumbent in frontline otoscopy with deep pediatric and primary-care distribution. PhotoniCare's former CEO advisory board member Steve Meyer was the last CEO of Welch Allyn, underscoring the competitive and partnership overlap in the otoscope category.
  • Hillrom (Baxter International): Hillrom, acquired by Baxter, distributes the Welch Allyn otoscope and broader vital-signs product lines into hospitals and physician offices globally. As the entrenched diagnostic-device incumbent in the same exam rooms PhotoniCare targets, it is the primary competitor that could add imaging features to existing otoscopes.
  • Heine Optotechnik: Heine is a global manufacturer of high-quality diagnostic instruments including otoscopes used by ENTs and pediatricians. As a long-established otoscope specialist with international distribution, it represents the incumbent product PhotoniCare must displace or differentiate against in clinical purchase decisions.
  • Natus Medical (Otometrics): Natus Medical, owner of the Otometrics brand, supplies audiology and hearing-diagnostic equipment including tympanometry and otoacoustic emission systems used alongside otoscopy. PhotoniCare's OCT-based middle-ear imaging competes with and could complement Natus's audiology diagnostic workflow in ENT clinics.

Direct peers

  • TytoCare: TytoCare offers a handheld, connected telehealth diagnostic device that includes a digital otoscope for remote ear examination, directly competing with OtoSight in enabling clinician visualization of the middle ear. Both companies target pediatric primary care and urgent care with FDA-cleared connected hardware.
  • Eko Health: Eko Health makes connected, AI-enabled handheld diagnostic devices (initially digital stethoscopes) sold into frontline care with FDA clearances and AI decision-support features. PhotoniCare's OtoSight follows a similar playbook of augmenting a familiar exam tool with novel optical/AI technology for primary-care clinicians.

Emerging players

  • Butterfly Network: Butterfly Network commercializes a handheld, AI-enabled point-of-care imaging device (whole-body ultrasound) sold to clinicians with FDA clearance and a recurring software/reimbursement model. PhotoniCare's OtoSight shares the handheld-imaging-plus-AI commercial model and frontline-care target customer base.
  • Remmie Health: Remmie Health develops connected otoscope and ENT home-diagnostic devices for parents and clinicians, targeting pediatric ear infection assessment with smartphone-attached visualization. It overlaps with PhotoniCare on ear imaging for the pediatric segment but from a consumer/telehealth angle rather than clinician OCT.
  • Interacoustics (Demant): Interacoustics, part of the Demant Group, manufactures clinical audiology and middle-ear analyzers (tympanometry, acoustic reflex) used in ENT and pediatric audiology workflows. It overlaps with PhotoniCare on objective middle-ear diagnostics and the same ENT/pediatric specialist buyer.
  • Cue Health: Cue Health developed a connected, FDA-cleared diagnostic hardware platform for point-of-care testing with an emphasis on clinician workflows. Like PhotoniCare, Cue pairs a regulated medical device with a digital/data platform, representing a comparable go-to-market and capital-efficiency archetype.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PhotoniCare social profiles

Digital presence

PhotoniCare compliance and trust

Trust signal

Compliance1 record

PhotoniCare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PhotoniCare leadership team

Management profile

Number of profiles

Profiles16 records

PhotoniCare funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PhotoniCare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhotoniCare

What does PhotoniCare do?

PhotoniCare develops and sells the OtoSight Middle Ear Scope, an FDA-cleared handheld medical device that uses Optical Coherence Tomography (OCT) to non-invasively image the middle ear. The device detects the presence or absence of fluid, characterizes fluid type, and visualizes fluid density, even in the presence of significant earwax, achieving 90.6% accuracy versus 50% with standard otoscopy.

Is PhotoniCare a public or private company?

PhotoniCare is a private company. It is classified as venture growth investor backed and is currently operating.

When was PhotoniCare founded?

PhotoniCare was founded in 2013. It employs 11 to 50 people.

Where is PhotoniCare based?

PhotoniCare is headquartered in Durham, United States, in the North America region.

How does PhotoniCare make money?

Two revenue lines are on record. OtoSight Middle Ear Scope Device Sales are the primary driver. The others are reimbursement / Procedure Billing.

Who are PhotoniCare's main competitors?

Broad incumbents on record are Welch Allyn (Baxter International), Hillrom (Baxter International), Heine Optotechnik and Natus Medical (Otometrics). Direct peers are TytoCare and Eko Health. Emerging players are Butterfly Network, Remmie Health, Interacoustics (Demant) and Cue Health.

Does PhotoniCare have an API?

No public API is recorded for PhotoniCare.

What industry is PhotoniCare in?

PhotoniCare's product category is Medical Diagnostic Imaging Devices. Its primary akta.pro industry code is HLAKAMAC, Otology & Neurotology (Ear/Hearing/Balance). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CrainsgrandrapidsGrand Rapids-based PhotoniCare scales up ear infection device salesPhotoniCare Inc. is projecting a fivefold increase in leases of its OtoSight ear-infection diagnostic device next year as it shifts from slow adoption to market-scale deployment. The Grand Rapids-based company also plans to introduce a redesigned version of the device by late 2026 to improve diagnosis of middle-ear infections in children.CrainsgrandrapidsGentex-backed medical device firm to relocate HQ to Grand RapidsPhotoniCare Inc., a medical device firm backed by Gentex, is relocating its headquarters from Champaign, Illinois, to Grand Rapids. The move supports the company's production of the OtoSight Middle Ear Scope in collaboration with Gentex.SecSEC FORM DPhotoniCare, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b), with total proceeds reaching $4,030,987 out of a planned $5,780,988. The offering, which began on December 1, 2023, has attracted 17 investors to date.SecSEC FORM DPhotoniCare, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt offering of securities under Rule 506(b). The company reported total offering amounts of $2.5 million, with $1.119 million sold to eight investors as of April 24, 2023. This filing serves as a regulatory notice for the private placement of equity or debt securities.SecSEC FORM DPhotoniCare, Inc. filed a SEC Form D notice of an exempt offering of securities under Rule 506(b), with a $3,000,000 total offering amount and $1,250,000 sold as of the filing. The minimum investment is $5,000, and 19 investors have participated, including non-accredited investors. No sales commissions or finder's fees were disclosed.Photonics SpectraVersatility in OCT System Design Opens the Door to New Clinical ApplicationsAdvancements in Optical Coherence Tomography (OCT) system design, including miniaturization and AI integration, are expanding the technology's clinical applications beyond traditional ophthalmology into optometry, primary care, and home monitoring. Companies such as Lumedica Vision Inc. with its OQ EyeScope and PhotoniCare Inc. with the OtoSight Middle Ear Scope are developing compact, lower-cost devices to improve accessibility for general practitioners and patients in developing regions.PR NewswirePhotoniCare Announces ISO 13485:2016 CertificationPhotoniCare, Inc. announced it has successfully completed ISO 13485:2016 certification for its quality management system used to design, manufacture, and service the OtoSight Middle Ear Scope. The certification, which specifies requirements for medical device quality management, demonstrates the company's ability to provide medical devices meeting regulatory and customer requirements. CEO Ryan Shelton stated the certification represents a milestone few medical device startup companies achieve and helps ensure compliance with US and global medical device regulations.PR NewswirePhotoniCare Appoints Former Welch Allyn CEO Steve Meyer to Advisory BoardPhotoniCare appointed Steve Meyer, former Welch Allyn CEO, to its advisory board. The company's OtoSight Middle Ear Scope uses OCT technology to assess middle ear fluid, with traditional otoscopy accurate only 50% of the time. Meyer brings experience commercializing frontline care products.PR NewswireOSF Ventures Invests in Device to Better Detect Middle Ear InfectionsOSF Ventures joined a $5.2 million Series A investment round in PhotoniCare Inc., a Champaign, Illinois-based medical device startup, alongside i2E Ventures, Sony Corporation of America, and Dreampact Ventures. The funding will support further development of AI technology and sales expansion for PhotoniCare's FDA-approved TOMi Scope, a handheld device using Optical Coherence Tomography to non-invasively image the middle ear and directly visualize fluid where infections reside — addressing a diagnostic gap where children are misdiagnosed up to half the time with current tools. OSF HealthCare will pilot the device at several urgent care locations to evaluate its clinical and workflow effectiveness.